Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer

OBJECTIVE: Prostate cancer (PCa) is considered the most serious cancer in the world. Nevertheless, the accuracy of current biomarkers, such as pathological staging, Gleason's score, and serum prostate-specific antigen (PSA) levels, is limited. FOXO1 is a key downstream effector of PTEN and a tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ning, Wu, Jiawen, Zhang, Tiancheng, Yang, Fan, Shao, Jinyan, He, Chang, Qin, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452405/
https://www.ncbi.nlm.nih.gov/pubmed/34552661
http://dx.doi.org/10.1155/2021/8773423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452405/
https://www.ncbi.nlm.nih.gov/pubmed/34552661
http://dx.doi.org/10.1155/2021/8773423

Ejemplares similares